Equity · Healthcare
ZBIO
NASDAQZenas BioPharma (ZBIO)
The line runs 31 USD on 12 August through 33 USD on 2 September, on a scale from 28 to 34. Days the market did not trade hold the previous close, flat.
- Market cap
- 2.2B USD
- Revenue, year to Dec 2025
- 10.0M USD
- EPS, diluted, year to Dec 2025
- −8.44 USD
- 52-week range
- 15 USD – 43.35 USD
- Avg volume
- 90.5K
as of Sep 2, 2026
Have Zenas BioPharma (ZBIO) insiders bought or sold shares recently?
ZBIO's newest Form 4 filing is dated 18 May 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 May 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 60,000 | 1.0M USD |
| 29 Apr 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 35,000 | 617K USD |
| 28 Apr 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 25,000 | 451K USD |
| 31 Mar 2026 | Lu HongboDirector | Buy | 78,768 | 1.6M USD |
| 31 Mar 2026 | Fairmount Funds Management LLCDirector | Buy | 150,000 | 3.0M USD |
| 31 Mar 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 34,000 | 657K USD |
| 30 Mar 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 20,000 | 365K USD |
| 13 Feb 2026 | Allen Patricia LDirector | Buy | 4,160 | 110K USD |
| 12 Feb 2026 | Allen Patricia LDirector | Buy | 15,700 | 390K USD |
| 11 Feb 2026 | Lu HongboDirector | Buy | 25,985 | 585K USD |
| 02 Feb 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 57,000 | 1.0M USD |
| 09 Jan 2026 | MOULDER LEON O JRChief Executive Officer | Buy | 20,000 | 331K USD |
| Bought | 20 open-market purchases | 1,528,648 | $29.05M |
Showing the 12 most recent of 20 open-market trades in this window. The figures above count all of them.
2 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Feb 2026 | Farmer Joseph LSee Remarks | Award | 974 | 13K USD |
| 05 Feb 2026 | Fox Jennifer A.See Remarks | Award | 1,592 | 21K USD |
Which funds hold Zenas BioPharma (ZBIO)?
7 of the 45 institutional funds we track reported a Zenas BioPharma position for the quarter ended 30 Jun 2026 — a combined 66.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Added | 815,150 | 20.7M USD | +196.4% |
| Millennium Management | Added | 660,470 | 16.8M USD | +38.5% |
| Balyasny Asset Management | Held (±25%) | 576,717 | 14.6M USD | −13.5% |
| Marshall Wace | Trimmed | 323,442 | 8.2M USD | −35.6% |
| Citadel Advisors | Added | 195,780 | 5.0M USD | +192.8% |
| AQR Capital Management | Trimmed | 31,100 | 789K USD | −39.0% |
| Point72 Asset Management | New position | 16,136 | 410K USD |
What has been filed or recorded for Zenas BioPharma (ZBIO)?
The filings we hold for Zenas BioPharma, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 606 shares | 17K USD notional · 0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 47 shares | 1K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,569 shares | 128K USD notional · 0.007% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 1,030 shares | 28K USD notional · 0.002% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.65 USD | Revenue $10M |
| 30 Sep 2026 | Financials | Total assets | 675.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 212.3M USD | at period end |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 544 shares | 15K USD notional · 0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.77 USD | Revenue $1M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.46 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −8.44 USD | Revenue $10M |
| 31 Dec 2025 | Financials | Revenue | 10.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −377.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −8.44 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.22 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.25 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.80 USD | Revenue $10M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −11.89 USD | Revenue $5M |
What do people ask about Zenas BioPharma (ZBIO)?
What did Zenas BioPharma shares close at?33.00
Zenas BioPharma closed at 33.00 USD on 2 Sep 2026, up 3.13% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Zenas BioPharma’s market cap?2.2B
Zenas BioPharma is worth 2.2B USD by market value as of 2 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Zenas BioPharma’s revenue?10.0M
Zenas BioPharma reported revenue of 10.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Zenas BioPharma insiders bought or sold shares recently?
No Zenas BioPharma insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 18 May 2026 (SEC Form 4). See Insiders
Which funds own Zenas BioPharma?7 of 45
7 of the 45 funds we track reported a Zenas BioPharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Millennium Management and Balyasny Asset Management. See Funds
When did Zenas BioPharma last report earnings?−1.65
Zenas BioPharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.65 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings